Head and neck cancer is a challenging disease that is expected to account for greater than
500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy …

Despite progress in the therapeutic management of patients with squamous cell carcinoma
of the head and neck (SCCHN), the mortality rate of patients presenting with advanced …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

In patients with squamous cell carcinoma of the head and neck (SCCHN), tumor recurrence,
secondary tumors, and comorbidities contribute to therapy failure, and treatment approaches …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Introduction: Despite improvements in treatment, survival rates of head and neck squamous
cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Current development of molecular targeted therapies in oncology is particularly active. This
paper is a review of the recent advances in the field of molecular targeted therapies for head …

Importance of the field: Head and neck squamous cell carcinoma (HNSCC) is the eighth
leading cause of cancer death worldwide. Despite advances in surgery and chemoradiation …